SPOTLIGHT -
Investigating Prognostic Markers for OS With LuPSMA Treatment in mCRPC
Andrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.
